Search This Blog

Friday, May 20, 2016

ASCO Data Underscore Lilly's Diverse Oncology Pipeline and Portfolio (NYSE:LLY)

Final phase 2 monotherapy data on CDK 4 and 6 inhibitor abemaciclib in metastatic breast cancer to be featured in oral presentation



ASCO Data Underscore Lilly's Diverse Oncology Pipeline and Portfolio (NYSE:LLY)

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.